SOLANA BEACH, Calif. , Aug. 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company is scheduled to release its second quarter on Wednesday, August 10, 2022 , after
Total new inbound prescriptions over 500 for first time, 24% increase over Q1; New cumulative prescribers up 23%; Net revenue increased by 11% SOLANA BEACH, Calif. , Aug. 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on
Patients With Symptoms of Diabetic Gastroparesis Now Have Direct-to-Patient Treatment Support Powered by UpScriptHealth SOLANA BEACH, Calif. and CHICAGO , Aug. 16, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company primarily focused on treatments for
SOLANA BEACH, Calif. , Sept. 06, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced that the Company’s President and CEO, David A.
GIMOTI recognized as a major disruptor in the gastroenterology field, including several large global pharmaceutical companies Vote for GIMOTI as 2022 Healio Industry Breakthrough Product via Survey SOLANA BEACH, Calif. , Sept. 14, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.
SOLANA BEACH, Calif. , Sept. 20, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray announced the United States Patent and
Company will exhibit Gimoti ® and meet with Key Opinion Leaders Healio Industry Breakthrough Product Award Nominee SOLANA BEACH, Calif. , Oct. 20, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal
SOLANA BEACH, Calif. , Nov. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company is scheduled to release its third quarter on Wednesday, November 9, 2022 , after
80% increase in GIMOTI ® net revenue over Q2 2022 56% increase of GIMOTI prescription fills in Q3 compared to Q2 13% increase of new prescribers of GIMOTI over Q2 SOLANA BEACH, Calif. , Nov. 09, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused
SOLANA BEACH, Calif. , Nov. 30, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced the United States Patent and
